/In Vitro Diagnostics
Boston Scientific Corp. has signed on to use newly public molecular diagnostics company BG Medicine Inc.'s galectin-3 test to determine which patients would benefit from cardiac resynchronization therapy...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?